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Abstract
Colorectal cancers display a vast range in the number of mutations per tumor. It is 
reasonable to assume that most mutations found in tumors are harmless passenger 
mutations and that only a small fraction of mutations found in these tumors are driver 
mutations that are responsible for initiation, progression and maintenance of the tumor. 
My research project was to compare types of mutations, genes targeted and specificity 
of gene targeting in high versus low mutation frequency tumors. My hypothesis is that 
there are qualitative and quantitative differences in the mutation spectrum of 
colorectal cancers that can be distinguished by the overall number of mutations 
detected in the tumors. To address this hypothesis, I analyzed whole-genome 
sequencing data from 223 colorectal cancers in the Cancer Genome Atlas. I compared 
cancers with >1000 mutations per tumor to those that had 0-999 mutations per tumor. I 
found that while the majority of genes mutated were found in both groups, distinct subsets 
of mutated genes did occur in the two sample sets that were mutated more than expected 
and more than in the other group. I found that those in the low mutation frequency set 
had a high specificity for mutations in known cancer genes while those in the high 
frequency set showed no significant clustering of mutations in known cancer genes. 
Altogether my data supported that there were qualitative and quantitative differences in 
the mutation spectrum of colorectal cancers based on the frequency of mutation in the 
individual tumors. 
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Chapter 1 
Genome sequencing, Cancer, The Cancer Genome Atlas, Mutation Rates, and 
Mutation Profiles 
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Introduction 
There were three technological breakthroughs that were critical to the success of 
my thesis project. The first of these was the successful completion of the human genome 
sequencing project that provided the template upon which my project could be built. 
Accompanying and enabling the human genome sequencing project was the 
development of technologies that enabled rapid and accurate sequencing of entire 
genomes. Finally, the development of highly curated databases storing both the normal 
genome sequence as well as the variation within the “normal” human genome together 
with the genomic sequences of human tumors was a critical preliminary step in my project. 
Parallel with this technological development, there was the conceptual advance that 
mutations in certain genes were critical in driving the process of tumorigenesis while 
mutations in other genes were simply passengers that were carried along as part of a 
stochastic process. Together these prior steps laid the foundation for my work. 
History of Human Genome Sequencing Project 
The Human Genome Project was initiated in 1990 with the goal of obtaining the 
full human genomic DNA sequence (1). The project did not seek to sequence 
heterochromatic regions such as centromeres or telomeres, but rather focused on 
euchromatic regions (1,2). When the project began, the NIH Genome program was 
headed by James Watson, who was succeeded by Francis Collins in 1993 (3). 
There was also a privately funded quest launched by Craig Venter and the firm 
Celera Genomics in 1998 (4). It was able to proceed much faster and more cheaply than 
the publicly funded HGP by making use of data that was released by the HGP. This effort 
was a profit seeking one, and Celera attempted to obtain patents on a large number of 
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genes (5). Celera promised to publish their results but there was suspicion that they would 
not permit free redistribution or scientific use of the data (5–7). Their intentions compelled 
the publicly funded project to publish their results first (6,7). In March 2000, then president 
Bill Clinton announced that the human genome sequence should be made freely available 
to all researchers and that access should be unencumbered (8). 
Initial drafts of the human genome became available in June 2000 and working 
drafts were completed by February 2001(1,6,7,9). The project was declared complete in 
April 2003 (10). The sequencing speeds during this 13-year time period increased 
dramatically as technologies improved, allowing the project to be completed 2 years 
earlier than initially planned. The genomic sequence continues to be updated and revised 
as directed by improvements in technology and accuracy of the underlying data (11). 
Sequencing technologies 
DNA sequencing technologies began being developed and used in the 1970s (12). 
Initially, labor intensive processes like Maxam & Gilbert sequencing resulted in maximum 
read lengths of about 100 bases at the time of its development (12). This was eventually 
overtaken by Sanger’s enzyme-driven sequencing process, which was able to achieve 
significantly reduced manual labor requirements and increased read lengths as 
improvements in gel and dye technologies were developed (12,13). Successive 
improvements have led to current processes including SOLiD and Illumina next 
generation high throughput sequencing technologies (13–15), and very powerful variants 
of Sanger’s original sequencing method that have been greatly improved by modern 
technological advances (13,16). Parallel improvements in multiple technologies, including 
electrophoresis gels, DNA base identification and detection, ranging from radiolabels, to 
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detecting pyrophosphate released during nucleobase-specific reactions, to various 
technology-specific fluorescent dyes, while machine driven automation technologies have 
brought DNA sequencing from a very labor intensive process resulting in very inefficient 
output, to a relatively easier and much cheaper process that enables the sequencing of 
enormous eukaryotic genomes within days, generating vast amounts of data that enable 
the detection of mutations throughout the genome. Various read selection techniques like 
exome sequencing (17,18), shotgun sequencing (19–21), cDNA sequencing of RNAs (19) 
and others have been developed that make specific types of experimental analysis 
possible. 
The Sanger sequencing method can now make use of colored fluorescent dyes 
allowing sequencing to proceed in a single reaction, paired with arrays of capillary gels in 
re-usable capillaries that allow the use of more powerful electric fields resulting in faster 
sequencing than could be achieved in slab gels (12,13). This technology was achieving 
read lengths of about 1300 bp in about 2 hours in the year 2000 (12,13). The benefit of 
these very long read lengths and arrays of capillaries allowing multiple samples to run at 
once, analogous to parallel “lanes” in older slab gels, enabled the rapid completion of the 
human genome project (13,16). 
The current Next Generation high throughput methods such as Illumina 
sequencing do not achieve the same long individual read lengths as Sanger sequencing 
(13,16), but what they lack in length, they more than make up for in read numbers, 
allowing sequencing runs to cover entire genomes with large numbers of reads per locus 
(13). The paired end nature of the sequencing (13) also allows software analysis to 
provide insights into phenomena such as alternative splicing, despite the shorter read 
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lengths. This technology can read 2 x 150bp in most current machines and 2 x 300bp on 
the MiSeq series (14,22). (2 x N refers to the first N bp on each “side” of the DNA strands). 
The machines range in output from 25 million reads per run to 6 billion reads per run, and 
run times range from 4-24 hours to more than 3 days, depending on the sequencer 
platform. 
Implications for research in human disease 
The completion of the human genome project’s main goal and the advent of these 
sequencing technologies has been a boon for all biological research, but in particular it 
enabled a much deeper probing of the genomic changes occurring in heritable diseases 
and various kinds of cancers than had previously been possible. 
History of TCGA 
The Cancer Genome Atlas (TCGA) is an ambitious project that seeks to map 
mutations and clinical characteristics of 33 types of human cancers (23). It was formed 
as a collaboration between the National Cancer Institute and the National Human 
Genome Research Institute. The TCGA dataset was generated by the TCGA Research 
Network, which is composed of a broad coalition of different research centers and 
laboratories. Much of the data has been made publicly available. Identifiable data, 
including a portion of the patient information and any germ-line mutations or relevant 
SNPs, as well as the raw sequencing data, require additional agreements and security 
procedures from researchers and their institutions in order to gain access.  
Across all tumor types, 11091 samples have been sent to the TCGA project for 
analysis. Out of these, 11077 have data available in the database. These are not evenly 
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distributed amongst the tissue types, probably due to varying rates of incidence. 16 tumor 
types have between 300-600 samples with data, 9 tumor types have between 100-300 
samples with data, 8 tumor types have less than 100 samples with data, and just one, 
breast invasive carcinoma has more than 600, with 1097 samples with data. I noticed that 
34 rows were in the table of tumor types on the TCGA website. I believe that while colon 
and rectal cancers are sometimes listed separately, the project treats them as the same 
cancer type when they provide the value of 33 for the number of tumor types. 
Concept of Drivers and passengers 
One of the big questions in cancer research is how many mutations are necessary 
to cause a tumor and what types of genes are involved (24). Bert Vogelstein and others 
have long proposed that multiple steps are necessary during the tumorigenic process (25). 
Early attempts to correlate mutations with tumor stage particularly in colon cancer 
resulted in a linear multistep process now known as the Vogelstein model (26). It 
proposed that each of three steps, initiation, promotion and progression could be 
correlated with specific mutations (27). Although this model has now been shown to be 
overly simplistic (28), it did provide the foundation for subsequent work on the concept of 
driver mutations. 
In two seminal papers by Sjöblom et al (29) and Wood et al (30) from Bert 
Vogelstein’s group, they were some of the earliest to describe the use of genome 
sequencing approaches to determine what mutations contribute to cancer pathogenesis, 
and to classify them appropriately (31). Mutations that do not contribute to cancer 
pathogenesis are called passengers, while the mutations that do contribute to cancer 
pathogenesis are called drivers (32). 
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In addition to this concept they examined mutation patterns, and frequency of 
mutations at different loci within populations of tumors (29–31). One of the ways they 
visualize these mutations is a 3 dimensional histogram “map”. On one axis is the 
chromosome number and on the other axis is the position along the chromosome. The 
height of the peaks is determined by the number of mutations within the region. Using this 
technique, they are able to find that certain genes are “gene mountains”, with very tall 
peaks, some are “gene hills” which are mutated an intermediate amount, while other 
genes are barely a blip on such a graph. They then examine how mutations cluster within 
the protein structure of a gene product as well as where the mutated genes fit within 
different signaling pathways. 
While these efforts were groundbreaking, there are some important details 
regarding how scientists might assign driver and passenger status to a mutation that need 
to be further explored. It is the combination of which gene is mutated, at which location, 
and the precise change, that actually determine whether the mutation will be pathogenic 
or not. It isn’t sufficient to consider a mutation a driver, simply because it happens within 
a gene known to have associations with cancer. 
Additionally, it is possible that there are some mutations that may contribute 
conditionally, if paired with other mutations. One such theoretical example would be Myc 
mutations in Burkitt’s lymphoma described by Bauer et al (33). In this case, a driver 
mutation in Myc leads to increased proliferation as well as increased rates of apoptosis. 
The increased rate of apoptosis balances the increased rate of proliferation preventing 
the tumor from increasing in size. A subsequent mutation in another gene that reduces 
the rate of apoptosis would lead to an increased growth of the tumor. Thus the initial driver 
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mutation is dependent on the second driver mutation for there to be a benefit to 
tumorigenesis. Other more complex scenarios may exist in genes that are part of 
signaling pathways. For example, multiple mutations disrupting different parts of a 
pathway might or might not produce a greater tumorigenic effect together than they would 
by themselves. 
Another example of conditional driver mutations would be a hemizygous mutation 
in a tumor suppressor gene. If one copy of a tumor suppressor gene was mutated 
somatically or was inherited with a defective sequence and did not produce a haplo-
insufficiency effect, and then a subsequent deletion or disruptive mutation that disabled 
the remaining functional copy on the other chromosome would be required to produce the 
tumorigenic effect. However, if only 1 such mutation occurred and the other functional 
copy remained, this mutation would not contribute to tumorigenesis. Technically this kind 
of mutation would rightly be considered a driver, but it would be a conditional driver, since 
its driver effect is dependent on the absence of both functional alleles. 
While silent mutations that do not affect the amino acid composition of a gene, or 
functionally synonymous amino acid changes, would likely be passenger mutations (since 
they do not affect the function of the gene), in some cases even mutations that destroy 
the function of a gene could also be considered passenger mutations. If the tumorigenic 
process requires a gain-of-function mutation in a gene to produce a tumorigenic effect, 
then mutations that inactivate the protein would actually be passenger mutations. 
I wanted to examine the effect that significant differences in mutation frequency 
had on the patterns of mutations that were found in tumors. Heritable defects in genes 
related to DNA mismatch repair are found in the familial syndrome, Lynch Syndrome (34), 
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which is known to cause very high rates of colon cancer (34), as well as broadly raise the 
rates of cancers in other tissues as well (34). This same repair mechanism can also be 
damaged or disabled in a somatic way in a subset of tumors in individuals that do not 
have a heritable defect (34,35). For my thesis project, it seemed that colon cancer would 
be a good model cancer type in which to examine mutation patterns to see if the idea that 
variations in mutation frequency in each tumor would significantly affect which genes were 
mutated in that tumor was plausible and to examine some details of the phenomenon if 
the hypothesis was true. 
Colon Cancer 
Colon adenocarcinoma is the third most common cancer in the USA (36,37). 
According to Cancer.org, 93,090 new cases of colon cancer and 39,610 new cases of 
rectal cancer were predicted to occur in the U.S. in 2015 of which 49,700 deaths from 
colon and rectal combined were anticipated (38). From 2003-2007 men showed an 
incidence of 57.2/100,000 and mortality of 21.2/100,000 and women had an incidence of 
42.5/100,000 and a mortality of 14.9/100,000. Understanding the defects that lead to 
these cancers may give us better tools to manage disease and potentially make available 
new avenues of attack to destroy tumors more effectively without serious harm to patients. 
A fraction (25%) of colorectal cancers result from inherited mutations (36), while 
the rest (75%) are a result of somatically acquired mutations. Colorectal cancers arise 
through several different pathways. One commonly observed mechanism in colorectal 
cancer involves defects in the DNA mismatch repair (MMR) pathway (39). MMR defects 
account for 15% of colon cancers (36) while most other cases (~85%) are caused by 
other processes involving chromosomal instability. In either case, cells that lose their 
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ability to repair replication errors and/or DNA damage have an increased mutation rate 
many times greater than that of normal cells (40,41). Presumably, any condition that leads 
cells to have either increased rate of mutation, an inability to recognize damage and 
undergo apoptosis, or a reduced ability to repair DNA damage or replication errors would 
increase the risk of cancer by contributing to tumor initiation, progression and metastasis. 
Even before the discovery of specific mechanisms that caused increased genetic 
instability and mutation rates, genetic instability had been considered to be highly 
important in human cancers (42). While mechanisms of DNA repair, their mutations, and 
the effects of mutations in these genes on colon cancers have been an area of intense 
research (43–46), the patterns of mutations that occur with different repair defects are still 
poorly understood (31). The specific types of mutations that occur could be significantly 
affected by the identity of the initially disrupted repair gene or the nature of the mutation, 
which could lead to distinct patterns of targeted mutations. 
I was curious to determine whether the spectrum of genes in which somatic 
mutations occurred in colorectal cancers differed depending upon the overall number of 
mutations that occurred in each individual tumor. I wanted to know if separating tumors 
with high numbers of mutations from those with relatively few mutations altered the 
patterns of driver mutations in the tumors. To do this, I proposed to analyze whole genome 
sequencing data from colorectal cancer tumors to test whether the tumors have different 
patterns of mutated genes based on the overall number of mutations that occurred in the 
tumors. My reasoning is that if I can show that there is a difference in types of mutations 
or genes that are being mutated between tumors with a very large number of mutations 
and those with a lower mutation frequency, future studies may discover that these 
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differences contain patterns that may be associated with the probability of recurrence, 
effectiveness of treatments, and patient outcome. 
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Chapter 2 
Broad analysis of TCGA COAD Sample Populations, Sample Grouping, and 
Differences Between Groups 
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Introduction 
In order to study the effect of mutation frequency on tumor genetics I needed to 
choose a tumor mutation dataset to use as an example. The Cancer Genome Atlas 
project has been collecting and analyzing tumor samples from numerous kinds of cancers 
and collecting the data into a publicly accessible database (47). Of primary interest to me 
was the effect of mutation rate on mutation spectrum in cancer. I chose to use colon 
adenocarcinoma as the model system for my analysis due to its association with tumors 
having genomic instability and high mutation rates (35,48). 
Colorectal cancer in general has high rates of genomic instability (49–51). Colon 
cancer genomic instability has previously been investigated in regard to diseases that 
produce microsatellite instability, such as hereditary nonpolyposis colorectal cancer (52–
54), (Lynch Syndrome), and similar conditions associated with defects in DNA mismatch 
repair proteins or failure to express them (35,55). 
Ongoing clonal adaption is a common and necessary trait of cancers leading to 
the concept that cancer is a Darwinian evolutionary process (50,56). As cancers and 
precancerous tissues undergo random selection during initiation and progression, their 
rates of mutation show variation (57,58). This variation in mutation rate drives the 
deterministic mechanism for both passenger and driver mutations. As a consequence, it 
is likely that those cancers that have lower mutation rates would likely show a 
retrospective bias towards mutations that actually contribute to the cancer phenotype 
while cancers that have a high rate of mutation would show a retrospective bias towards 
more stochastic mutations. This is because a low rate of mutation would provide greater 
opportunity for the developing tumor to undergo clonal selection before many mutations 
 14 
 
accumulate. In my analysis, I lacked any physical access to any cells from the tumors 
that I proposed to examine. Therefore, I could not measure the mutation rate in these 
tumor cells directly. However, numbers of mutations occurring in each cancer could act 
as a surrogate for mutation rate. Therefore, by comparing the number of mutations that 
are found in individual tumors, it may be possible to correlate mutation frequency with its 
effects on clonal selection.  
Other factors may also have an effect on the retrospective bias for mutations. 
There may be structural or chemical factors that could lead specific genes to be more 
likely to experience mutation than others depending on the mechanisms driving the 
change in rate of retained unrepaired mutation. It is also possible that the cancer staging 
may correlate to how severely genetically damaged the tumor cells have become 
although I did not actually expect later staging to correlate very strongly with mutations, 
since high mutation rate tumors seemed to have more favorable outcomes in general 
than normal tumors. 
Together, these factors suggested to me that it was likely that there would be a 
qualitative difference in the spectrum of genes that underwent mutation during cancer 
that was dependent on the number of mutations in the individual tumors.  
Hypothesis 
As the number of mutations within a tumor increases, there will be a shift in which 
genes undergo mutations in tumors collected from cancer patients. Tumors with low 
numbers of mutations should show a bias towards mutations in cancer driver genes that 
should not be apparent in tumors with high numbers of mutations. 
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Methods 
The TCGA dataset mutation data is stored in MAF format. A program was prepared 
to count mutation entries in the dataset according to sample ID, mutation type, and Gene 
Symbol. Individual counting functions were prepared for each of these with corresponding 
tab separated output. Originally there was a pair of files, with data resulting from SOLiD 
sequencing being kept separate from data that resulted from Illumina sequencing. The 
bulk of the data were in the Illumina dataset, so to avoid potential complication in the 
analysis, I chose not to use the SOLiD file. 
As noted, I lacked physical access to any cells from these tumors with which to 
attempt to measure a mutation rate directly. The TCGA project itself did not include 
measurement of mutation rate as one of their analysis methods either. As a result, I had 
to use an indirect method to get a rough handle on the mutation rate. I decided to use the 
total count of somatic mutations within the TCGA dataset as a proxy for this. I chose not 
to analyze larger chromosomal structural changes as I felt that this would complicate the 
analysis unnecessarily. 
I wrote a program in Python to count single nucleotide mutation types (substitutions, 
insertions, and deletions), separating the counts according to original base and resulting 
base. I also enabled this tool to count mutations by Sample ID and Gene symbol. This 
was accomplished using a counter object sub-classed into multiple other types defined to 
use different counting rules. My method was to use strings in a map data type that stored 
integers using strings as the key. Gene Symbol and Sample ID were used as keys, and I 
constructed a key for the mutation types using the original and changed bases, using 
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dash as a placeholder for indels. The script allowed any combination of the counters to 
be used simultaneously, each outputting their counts to separate files. 
To determine the effect of the mutator phenotype on these counts, I also decided 
to divide the tumors into two groups, a high mutation group and a low mutation group, 
and ran the same counting process on the separated groups as I ran on the entire dataset 
in the previous analysis. To accomplish this, I wrote an additional program to use the 
output of the sample ID counting function in combination with integers provided by the 
user, to split an MAF file, entry by entry, into grouped outputs. These output entries, still 
in MAF format, were then run through the original counting script again and the results 
were examined. 
Count boundaries used to split the data were selected based on the location in a 
sorted graph of total mutation counts where it seemed there was a significant difference 
in the number. I did check the MSI status of these samples at a later time, and the results 
of this split matched fairly well with this boundary. The MSI high samples mostly fell into 
the higher mutation group where the MSI low were mostly in the lower mutation group. 
Clinical staging was analyzed for correlation to mutation counts as well. 
I requested clinical information alongside the somatic mutation data, when I first 
obtained the TCGA dataset. These files were examined for their structure and information 
content to determine where the relevant data were, and then were used to combine this 
information into a useful table containing the information of concern. The sample IDs were 
used to cross compare the various categorizations and mutation counts to determine if 
there were any statistically significant correlations. 
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Results 
Population Level Mutation Information 
The first analysis performed was to count the number of mutations in each sample 
and view this data. I chose to sort the results from highest to lowest and plot them in a 
bar graph. The values of the mutations per tumor showed a distribution of samples with 
a long trailing tail of lower value counts and a relatively shorter collection of samples with 
very high count values. There seemed to be at least two different trends in the population, 
which could be the result of shifts in mutation rate. If one was to draw trend lines for the 
low mutation side of this plot, and the high mutation side of this plot, separately, they 
would have very different slopes. 
In order to compare the two potential trends in the populations, it was necessary 
to choose a breakpoint between the two populations. The choice of a breakpoint at 1000 
mutations seemed like a reasonable boundary to split the samples into two groups since 
it was close to the long low count tail, and it seemed to be a point where there was a shift 
in the trend. I divided the tumors into two separate populations of ≥1000 mutations/tumor 
and <999 mutations/tumor. I then examined the identity of the genes that were mutated 
in these two separate groups by running the gene mutation counter on the split MAF files. 
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Figure 1. Number of mutations per tumor (TCGA database: COAD Illumina 
Dataset) 
Each blue bar is a count of all mutation entries for an individual sample in the dataset 
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When looking at the results for all genes, since a very large portion of the human 
genome was included in the set of genes with mutations, there was an expected 
significant amount of overlap between the two groups of tumors. In total, both lists 
represented 17,046 genes, which is a majority of the predicted 20,000 to 25,000 human 
genes (2,59). However, even within this very large gene set, the two groups had distinct 
sets of genes. So I decided to look at overlaps within smaller, more significantly mutated 
subsets. 
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Figure 2. Venn diagram of all mutated genes 
Lists were generated by counting mutations from the split groups, and binning 
according to gene symbol using the counting program described in methods. 
The High mutation group is shown in blue while the low mutation group is yellow. The 
overlapping shared region is a darker yellow. A large number of mutated genes are 
shared between the groups, but there are unique genes in both groups. 
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Comparison of Most Mutated Genes between groups 
This Venn diagram was created by selecting the genes with at least the same 
mutation counts as the 100th most mutated gene in each group. While there was again 
significant overlap, there were still potentially relevant differences. Some of these 
differences appeared to actually lie within the overlapping region of the original all-
inclusive Venn diagram if the gene in the top 100 in either group was mutated within both 
populations, but was not mutated at the same frequency in the two groups. This, however 
would still be a potentially interesting qualitative difference. 
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Figure 3. Venn Diagram of Mutated Genes, First ~100 
Lists were generated by selecting all genes that had at least the same number of 
mutations as the 100th after sorting by mutation count. The list of gene based counts 
was generated using the counting program on the split data files. The High mutation 
group is yellow, the low mutation group is red, and the overlap is orange. 
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As in the previous diagram, this Venn diagram was created by selecting the genes 
with at least the same mutation counts as the 50th most mutated gene in each group. This 
smaller list again recapitulated the pattern observed in the larger previous lists. This same 
pattern of overlapping and non-matching genes remains visible even when filtering the 
list according to the most mutated genes. This resembles a chaotic equation plot, like a 
fractal (60–62), where the appearance remains similar regardless of magnification. 
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Figure 4. Venn Diagram of Mutated Genes, First ~50 
Lists were generated by selecting all genes that had at least the same number of 
mutations as the 50th after sorting by mutation count. The list of gene based counts was 
generated using the counting program on the split data files. The High mutation group 
is yellow, the low mutation group is red, and the overlap is orange. 
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Most Mutated Genes Lists 
When the list of genes from each of the tumor sets was compared using the DAVID 
functional annotation software (63,64), the list derived from the lower mutation group 
showed a much more targeted set of cancer related genes. While the list derived from the 
higher mutation group did still contain known cancer related genes, there were larger 
numbers of seemingly unrelated genes, as well. These unrelated genes were probably 
passenger mutations. 
Functional clustering by gene ontology of the list of mutated genes from the lower 
mutation group using DAVID resulted in one functional cluster that listed many cancer-
related sub-terms in addition to two other functional clusters which referred to colorectal 
cancer specifically. In contrast, results for the list of mutated genes from the higher 
mutation group only had one cluster specifically containing cancer terms, limited to 
“pathways in cancer” and “small cell lung cancer”. 
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Figure 5. List of ~100 most mutated genes. Lists were generated by selecting all 
genes that had at least the same number of mutations as the 100th gene after sorting 
by mutation count. The list of counts grouped by gene symbol was generated using the 
counting program described in the methods section on the split data files. 
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Correlation Between Mutation Count Group and Cancer Staging 
During one of my Research in Progress meetings, someone from the audience 
raised a question about correlation between tumor staging (65) and mutation rate. I chose 
to examine this by pulling the publicly available clinical data and matching it with the 
mutation counts. The high mutation count group has a higher proportion of Stage II and 
Stage IIA tumors and a lower proportion of Stage III and IV tumors than the low mutation 
count group (Figure 6). The proportion of Stage I tumors was very similar in the two 
groups, but was slightly higher in the high mutation group (Figure 6). The differences for 
Stage II (without a subtype) were statistically significant, as were the difference between 
the pooled counts for all subtypes of Stage II together (Figure 6). Differences for Stage III 
only showed statistical significance when pooled (Figure 6). Stage I and IV did not pass 
requirements for statistical significance via a two tailed Z test of proportions (Figure 6). 
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Figure 6. Tumor Staging 
This data was pulled from text files containing clinical information on the cancer 
samples in the TCGA database. A two-tailed two sample Z test of proportions was 
performed on the counts of tumors grouped by stage. 
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Correlation Between Mutation Count Group and Mutations in Repair Genes 
Similarly, during one of my committee meetings, the question was raised as to 
whether there was a correlation between mutation frequency and mutations within 
mismatch repair, and other DNA repair genes. I included the main genes known to be 
associated with Lynch Syndrome (66–68), as well as some genes involved in mismatch 
repair (69). PolG was included as well due to there being an association with colorectal 
cancer (70,71), and PolG being involved in mitochondrial DNA repair (70). I queried the 
mutation counts file for the specific genes of interest and compiled a list (Figure 7). There 
were more mutations within the DNA mismatch repair related genes in the higher mutation 
group. These could be functionally destructive mutations leading to a retention of 
unrepaired DNA damage, or they could be symptomatic of an already disrupted repair 
system, or an aberrantly regulated cell cycle checkpoint, or some other mechanism 
leading to an increased mutation rate. Out of these genes, PMS1, PMS2, RFC2, RFC5, 
and RFC6 did not meet statistical requirements for significance in the difference of the 
counts. However, given the low frequency of mutation in these genes, even with the two 
tailed Z test of proportions, some of these counts were hard to interpret. The one mutation 
in RFC3 for instance, might not actually be biologically significant or relevant, even if it 
was statistically significant, as it resulted from only 1 mutation in the smaller group. 
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Figure 7. Genes Related to Repair and Replication 
Lists of counts grouped by genes were searched for the entries corresponding to genes 
of interest. A two-tailed two sample Z test of proportions was performed on the counts. 
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Following up the mismatch repair gene mutation list, I also looked into DNA 
microsatellite instability status, which is associated with the mismatch repair deficiency 
phenotype (46,54,72,73), as a mutation within these genes would not necessarily produce 
the well characterized phenotype. The MSI status was also available within the clinical 
data. The high mutation count population was enriched for tumors designated as MSI-H, 
while the population with lower mutation counts was enriched for MSI stable tumors and 
those categorized as MSI-L. 
I plotted this breakdown of the tumors according to MSI categories (Figure 8) to 
show the total somatic mutation count in a manner similar to Figure1. A few of the MSI-H 
tumors had comparatively lower counts compared to the other MSI-H tumors while 1 MSI-
H tumor showed a very high mutation count in comparison to the others. Most of the MSI-
stable tumors were fairly low in mutation count, but a small number of them had between 
300 and 600 mutations, which was significantly more than the rest (Figure 8).  
A handful of MSI stable tumors had even more mutations than those in the low 
mutation population (Figure 8). These samples ranged from more than 7 thousand 
mutations to one with approximately 2000. Most of the MSI-H samples were between 
1000 and 2000 mutations. A handful were between 2000 and 3000, and one was above 
5000.  
The difference in proportions between the high and low groups for all of these 
classification groups were highly statistically significant according to a two tailed Z test. 
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Figure 8. DNA Microsatellite status of the samples. Table shows grouped counts 
and the results of a two tailed z-test of proportions. Charts are the same numbers as in 
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Figure 1, but grouped by MSI status and split by mutation count group. The first bar 
graph is the low mutation count group, and the second is the high mutation count group. 
Red is MSI-H, Yellow is MSI-L, and Blue is MSS 
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Testing alternate split value for high and low groups 
The value of 1000 for splitting the high and low mutation cancers into two groups 
was somewhat of an arbitrary choice. It happened to coincide nicely with the population 
of MSI-HIGH tumors as compared to the normal tumors and MSI-LOW tumors. In the 
interest of seeing how well the observed differences exist at other break points, I also split 
the samples into two groups at 300 mutations, and compared the lists of mutated genes 
as I had done for the 1000 breakpoint. 
The overall Venn diagram resulting from this split is shown in figure 9. As before, 
there are differences in which genes appear with mutations, with some uniquely mutated 
genes in either group. 
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Figure 9. Venn Diagram of High and Low mutation groups split at 300 mutations. 
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Figure 10 corresponds to Figure 3, but for the 300 mutation split point. As before, 
when selecting the 100 most mutated genes from either group, there were shared genes 
as well as significant numbers of unique genes. This pattern supports the idea that there 
really are differences between the high and low mutation groups, and that the split point 
of 1000 is not the only breakpoint that reveals these differences in mutation. There were 
slightly more shared genes and fewer unique genes, although it was hard to determine 
how significant this difference was, as the numbers are still very similar. 
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Figure 10. Venn Diagram of ~100 most mutated genes in High and Low mutation 
groups split at 300 mutations. 
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Figure 11 corresponds to Figure 4, but for the 300 mutation split point. As with the 
1000 split point, this more restricted list maintained a similar pattern of unique genes and 
shared genes to the ~100 gene list. With this split point however, there were more shared 
genes and fewer unique genes within the high mutation group. This was likely due to the 
fact that including the samples with 300-999 mutations in the higher mutation group 
shifted the mutation patterns of the group slightly, but the overall fact that there were still 
differences remains. 
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Figure 11. Venn Diagram of ~50 most mutated genes in High and Low mutation 
groups split at 300 mutations. 
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Discussion 
These tumors exhibited an interesting divide between the high and low mutation 
frequency groups that held at both the large scale and when focusing on the most mutated 
genes. There did appear to be a relationship to DNA mismatch repair genes in the high 
mutation frequency group, and curiously, lower staging seems to correlate with the high 
mutation frequency group tumors instead of higher staging as one might be inclined to 
expect. 
When looking broadly at the most mutated genes between these low and high 
mutation groups, it was apparent that the lower mutation group exhibits a bias towards 
mutations in cancer focused genes, while the higher mutation group had some cancer 
genes in its list but also many other kinds of genes. It was apparent that there was indeed 
a difference between these populations. Thus a more detailed examination of those 
differences became of interest. 
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Chapter 3 
Mutation Rate Group Differences in Mutation Types and Gene Mutation Counts; 
Positively Deviating Outliers in Mutation Count & Gene Length Trend 
  
 44 
 
Introduction 
In the previous chapter, I had noticed when examining the counts of mutations by 
Official Gene Symbol, that there was a general trend of mutation count with gene size. 
As an example, Titin (TTN; OMIM 188840) was generally near the top of both lists when 
sorted by mutation count. TTN is encoded by an 82kb mRNA making it one of the largest 
genes in the human genome (74). This suggested that its mutation frequency might be a 
consequence of its size. However, after examining other genes from annotation 
databases I noticed that there were some other genes that appeared more frequently 
than their size would dictate. 
The concept of mutation spectrum, also called genome or mutation landscapes, 
refers to the total of all mutations contained in the genome of tumor cells, usually classified 
as passenger or driver mutations (28–32,75). It is sometimes visualized in a histogram-
like manner using mutation counts as the height variable, across the chromosomes on 
one axis and the chromosome number on the other axis. 
There are many types of mutations and each can have varying causes. Small scale 
mutations include substitutions, insertions, and deletions each of which involves a single 
nucleotide or multiple nucleotides, and small scale inversions, which would necessarily 
involve more than one nucleotide. Large scale mutations, involving very large changes to 
chromosomes including copy number changes, duplications, deletions, and movement of 
large segments of DNA within or between chromosomes, or even gain or loss of entire 
chromosomes, would require a more complex analysis and were not included in my 
project. 
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Mutations within genes can have complications in their assignment. Due to splicing 
of transcripts there are sometimes multiple transcript variants that use different 
combinations of exons. A mutation may fall within one of the optional exons and only 
affect some transcript variants.  
I used an approach of examining at the gene scale rather than differentiating 
between transcripts. There could perhaps be something of interest involving alternative 
transcripts, but it would introduce complexities into my analysis that were not directly 
relevant to answering the question I was seeking to answer. 
Hypothesis 
I hypothesized that the collection of genes mutated within the low mutation count 
population would tend to be more selective and have a greater degree of cancer 
specificity than the higher mutation count group. Further, in the higher mutation count 
group, I expected the influence of gene length on mutation count to increase significantly 
and the influence of selection, related to clonal evolution within the tumors, to be less 
significant in the high mutation population compared to the low mutation population. 
Methods 
In an idealized mutation scenario without the influence of clonal selection, one 
would expect a linear relationship between gene size and the number of mutations that 
would appear in a population of cells over time. If the mutations found in the tumors were 
to become more random and less selected, then there ought to be an increase in the 
association between gene size and mutation count within a gene. I wanted to be able to 
determine which genes were outliers from this trend. The impact of selection would place 
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some genes outside of this trend, in a positive direction if the mutations provided selective 
benefit or negative direction if they were deleterious for the cells in some way. I am 
primarily interested in those genes which had positive deviation from the trend. 
I wrote a program to count mutation types both for the group as a whole and with 
a breakdown by sample. I also wrote a program to perform two tailed t-tests on the 
resulting tables of values, as well as their proportions against the total number of 
mutations within each tumor using a matching table structure, and to perform a linear 
regression on count data binned by gene symbol, and use that regression to obtain 
studentized residuals for the mutation counts of each gene. These were used to assess 
differences between the high mutation group and the low mutation group. The residuals 
and linear regression aimed to reduce the impact of gene length on the ranking and to 
identify genes that were positively deviated outliers in the roughly linear gene length and 
mutation count relationship. 
The results of mutation count grouped by gene symbol were used to plot gene size 
against total mutation count. I used Excel’s trend-line feature to place a trend line on this 
graph. Note that this trend line was not produced by the same software that performed 
the linear regression, and so may not be exactly the same as the line that was used to 
produce the residuals. 
Files containing gene lengths were obtained from the genome browser table 
viewer. These were matched up with the entries in the MAF files in order to normalize 
against the effect of gene length. Genes with multiple transcript variants had isoform 
lengths averaged. The counts were divided by the lengths and the number of samples in 
their respective group.  
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I added these lengths to the selection of ~100 genes with the highest mutation 
counts from the previous chapter to show the variation of the gene lengths at the high 
end of the mutation counts. For these, I examined the 100th gene in the count-sorted list, 
and included any others beyond that point which had the same number of counts, in each 
group. I also repeated this using the studentized residual values instead of the counts, to 
show the genes with the highest residuals. 
Results 
Differences in Mutation Types 
Figures 12,13,14, and 15 show the mutation type counts for the low and high 
mutation count groups respectively. Figures 14 and 15 are calculated values based on 
categories of mutation type, and mutations that are technically chemically 
indistinguishable due to DNA’s base pairing. Figures 16, 17, and 18 show these values 
converted into percentages based on the total sum of mutations within each sample. 
Figure 18 corresponds to both Figures 14 and 15, which were kept separate due to size. 
These mutations are labeled using a “reference_mutation” pattern, with a dash “-
“ standing in for missing bases in insertions or deletions. MNC stands for multi-nucleotide 
change. Due to difficulty and complexity in the analysis of mutations involving more than 
one base, I opted to bin these types of mutations into one category. These types of 
mutations were less frequent than single base mutations in general, but are still prevalent 
enough to be potentially important.  
The raw data and some calculated values are being shown in Figures 12-18 to 
facilitate explanation of some details about the mutation types, and because it was 
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feasible to fit these tables into this document, albeit in a very dense and compact form. 
The results of the t-test are shown in Figure 19. 
Figure 12 depicts the result of the uncategorized mutation counts within the low 
mutation count group. There was quite a lot of variation in mutation count within this group, 
and the tumors with low numbers of total mutations frequently had zeroes for certain 
values. The values of corresponding mutations (such as C_T and G_A) usually matched 
quite well within each row. C_T and G_A were the most common mutation type by far, 
which was probably frequently the result of 5-methylcytosine deamination. 
Figure 13 is the same type of table as Figure 12, but for the high mutation group. 
The counts were broadly raised, but there was a subset of these tumors that had very 
large counts for some types and not others. For instance, the 2nd to last row was a sample 
that had 799 C_T mutations, but only 1 C_G mutation and very low numbers of insertion 
mutations. 
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Figure 12. Low Mutation Count Group Mutation Type Counts. 
ALL is the total sum of mutations for a given sample. MNC stands for multi-nucleotide change. All other columns were 
composed of a pattern of REFERENCE-BASE_MUTATED-BASE, with a dash standing in for missing bases in the case 
of insertions or deletions. (Insertions were of the form -_INSERTED-BASE and deletions were of the form REFERENCE-
BASE_-). 
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Figure 13. High Mutation Count Group Mutation Type Counts 
Columns are as described for Figure 12. 
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I created additional data columns based on potentially relevant categories by 
adding together the values present in the above table. These values included insertions, 
a sum of all single-base insertions, deletions, a sum of all single base deletions, indels, a 
sum of both of those, transitions, and transversions, sums of the mutations that matched 
these definitions, and a set of mutations that would be considered indistinguishable due 
to double-strand base-pairing ({A-T and T-A}, {C-G and G-C}, {C-T and G-A}, {A-C and 
T-G}, {A-G and T-C}, {C-A and G-T}). The values for these sums and their proportions 
were also included in the t tests. 
Figure 14 depicts these values for the low mutation group. Insertions and deletions 
showed quite a bit of variability. In some tumors the insertions and deletions roughly 
matched, while in others the numbers were very different. Indels in general were less 
frequent than other single-base mutations. With the chemically matching mutations added 
together, the dominance of the C_T mutation became even more apparent. 
 
In Figure 15, the data for the high mutation group mutation type categories drive 
home again how many more mutations these samples had on average than the others. 
C-T and G_A were once again the most common, with C_A and G_T generally having 
slightly more mutations than A_G and T_C. It was interesting that the other 3 mutation 
types were still fairly low. There were quite a lot of single base indels in these samples as 
well. 
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Figure 14. Low mutation Group Mutation Type Count Categories 
ALL is the same as Figures 12 and 13 and was repeated for visual comparative purposes. 
INS was a sum of all insertions. DEL was a sum of all deletions. INDEL was a sum of all insertions and deletions. Transition 
was a sum of all transition mutations, and transversion was a sum of all transversion mutations. 
The remaining columns were sums of chemically equivalent mutation types. These were represented using a pattern of 
base1-base2 with a ‘|’ character separating the pair of mutation representations. Thus an A to T mutation, which could be 
considered biochemically equivalent to a T to A mutation due to base pairing was represented as “A-T|T-A”, and had a 
count formed by the sum of the A_T and T_A columns from the previous table. 
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Figure 15. High mutation Group Mutation Type Count Categories 
Columns are as in Figure 14. 
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It was apparent that due to the difference in magnitude of the numbers between 
the groups that most if not all of these mutation categories would have statistically 
significant differences. I created equivalently structured tables where the values for each 
sample were divided by the total number of mutations in that sample, to obtain percentage 
proportions.  
Figure 16 shows the proportions for the low mutation population. After controlling 
for total mutation count by converting these numbers to percentages, the ratios were 
much less variant for the C_T and G_A mutations. There were some variations among 
other mutation types that might be more significant. MNC mutations were fairly 
consistently in the single digit percentages, although were more frequent in some tumors.  
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Figure 16. Low Mutation Group Mutation Type Proportions 
Columns are as in Figures 12 and 13, and the data are now shown as percentages instead of counts. 
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Cross comparing the indel percentages from Figure 17 and the MNC percentages 
from Figure 16, it seems they had very similar values, although not always matched up in 
magnitude within any one tumor. C_T and G_A mutations accounted for between 40%-
60% of the mutations in most of the samples. C_A and G_T mutations were somewhat 
common single base changes, and accounted for about 10%-20% of the mutations in 
most of the samples. The A_G and T_C mutations were slightly less common than that 
with most ranging from 6%-20%, but tended to be low more often. The other three 
mutation type categories mostly ranged between 0% and 5%, and were closer to values 
between 3-5%. 
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Figure 17. Low Mutation Group Mutation Type Category Proportions.  
Columns are as in figures 14 and 15, but depict the data as percentages. 
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Figure 18 contains both the mutation type proportion table and the mutation 
category proportion table for the high mutation group. The C-T and G_A mutations 
seemed similar in the high group to what was found in the low group. The indels seemed 
to be somewhat raised in general (although some of these tumors did not experience this). 
The A_G and T_C mutations seemed to be a bit more common as well in this group. The 
other three types were a bit less common than in the low mutation group. This was relative 
to the total number of mutations, so the actual values were higher on average by quite a 
lot than in the low mutation group, but the ratios did seem to be a bit different. 
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Figure 18. High Mutation Group Mutation Type (and Category) Proportions 
Columns here are as shown in tables 9-14. These values are represented as proportions of total mutation counts per 
sample. 
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I then performed a t test on both the raw data and the proportions. C_G mutations 
did not pass requirements for significance of difference base on counts, while its chemical 
equivalent G_C did, but only barely. The combined category for these, also did not pass, 
having a p value just slightly higher than 5%. All the rest of the count values were 
significantly different, as expected. 
In terms of proportions, several mutation types counted separately did not pass 5% 
requirement for significance, including A_C, C_A, G_A, G_T, T_G. In the categories, the 
A_C and T_G, the C_A and G_T, and the transitions categories did not pass requirements 
for significance  
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Figure 19. Results of Two Sided Welch Two Sample T Test on Mutation Type Data 
The first pair of tables is the result of the t test on the raw count values. The second pair of tables is the result of the t test 
using proportions as input instead of the raw counts. Within each pair the first table contains the results for the individual 
mutation types and the second table for the categories. 
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Differences in Mutated Genes 
Plotting the mutation counts binned according to gene for the entire population of 
tumors resulted in a scatterplot that was quite messy. It was apparent however that there 
was a collection of a small number of genes that mutated significantly more than their 
similarly sized counterparts. In the first plot, showing all of the points, one can see several 
genes that mutated to the most extreme levels, and with the slightly more zoomed in 
scatterplot, there were quite a number of highly mutated genes that deviated from the 
general trend to a lesser, but still quite obvious, extent. I became interested in the 
appearance of this kind of plot when produced using the split populations. 
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Figure 20. Scatterplot of Gene based counts from non-split data 
These two plots both depict the total sum of all mutations per gene for the entire set of 
samples. The first plot has a larger maximum on the x and y axes in order to see the 
values for the most mutated genes and the largest genes. The second plot is more 
zoomed in to give a better view that is not possible in the first image. 
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The one difference that became obvious right away was the number of mutations. 
The population size of the high mutation group was 39, while the low mutation group was 
180. These counts had not been normalized by population size, and yet the plots were 
covering approximately the same region in terms of count values. Additionally, there were 
not quite as many obvious outliers on the low-length side of this scatterplot in the higher 
mutation count group. The dot near the top right corner, which happened to be TTN, 
seemed to have approximately twice the number of mutations, indicating that it garnered 
several mutations in several of the tumors. 
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Figure 21. Gene Mutation Counts Derived from split data 
These two plots are produced similarly to the first plot in Figure 20. Each is produced 
from one of the mutation count groups. The first plot is the low mutation group and the 
second plot is the high mutation group. 
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Zooming in more closely around the bulk of the points, I observed that the high 
mutation group again had more high counts trending toward the right side of the plot, and 
also that the main blob of plotted points was more closely packed in addition to being 
“taller”. The bulk of the population of genes within the low mutation count group were 
below a value of 10, and the densely packed region was fairly flat from about length 8000 
and below, with a region of slightly less density between 8000 and 10000. The high 
mutation group, in addition to having a “taller” dense collection of points, also had its 
dense region peaking at genes approximately of length 6500, with its less dense region 
spanning 6500 to 8500. This less dense area trailed off in both the positive Y direction 
and positive X direction. The overall impression was that the mutations in the high 
population were more associated with gene length than those in the low population, for 
at least a visibly noticeable sub-population of genes. 
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Figure 22. Gene Mutation Counts Derived from split data Zoomed in 
These two plots are produced similarly to the second, more zoomed in plot in figure 20. 
Each is produced from one of the mutation count groups. The first plot is the low 
mutation group and the second plot is the high mutation group. 
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The next question was which genes were most significantly mutated. After I 
returned to the list previously examined, and added in gene lengths, it became apparent 
that there was a difference between the two lists in terms of gene lengths. The high 
mutation population count list, when sorted by count value from high to low, showed a 
stronger trend of the length values following a high to low order than the low mutation 
count list. There were several genes that bucked this trend, which might be due to 
mutational hot spots or the effects of clonal selection.  
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Figure 23. Gene Counts with Lengths from Split Populations. 
This is the same list as from Figure 5, but with the calculated gene sizes added. 
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I decided to try some methods to reduce the effect of gene length, and after 
speaking to Yu-Bo Wang and Dr. James Grady, both experts in statistics, I went with 
using a linear regression to obtain studentized residuals. The values of these residuals 
should reflect the degree to which the count was an outlier from the trend line for that 
population, with negative values indicating a negative deviation from the trend and 
positive values indicating a positive deviation from the trend. I compiled a list of these 
computed residual values and sorted the list from high to low. The 100 highest values 
from each population are listed in Figure 24. 
A more advanced statistical model than a linear regression might be desirable for 
future analyses, as there were multiple overlapping effects other than just gene length. 
Some genes would exhibit negative selection for damaging mutations, due to cell viability 
needs and either show low mutation counts or zero counts. Other genes would have 
positive selection in tumors from any deactivating mutations, due to not requiring subtle 
mutations in order to contribute to the tumor phenotype.  
Another set of genes would exhibit positive selection on very specific subtle 
mutations, but negative selection or no selection at all (depending on the tumor’s existing 
genetic background) for any deactivating mutations, making some mutations within this 
class of genes passenger mutations despite the gene being a cancer-related gene.  
If a tumor was already carrying a subtle mutation in one of these genes, then a 
destructive change to the function of that gene would be unlikely to persist within the 
tumor unless it occurred within the second copy of the gene on the other chromosome for 
a gene where losing the remaining normal copy would not be detrimental to cell viability. 
The chances of such a double mutation within the same gene on the same chromosome 
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were also remote for most genes, however this effect might also impact other required 
genes downstream in the functional pathway from the subtly affected gene.  
In addition to these effects from subtle mutations and disabling damaging 
mutations in cancer related genes, there were also a very large number of mutations that 
had little to no effect on the genes they occur in, due to being a redundant codon swap, 
or causing a functionally synonymous amino acid change. These kinds of mutations 
would inherently be passenger mutations, and it is important to note, they could also occur 
within cancer related genes. There would also be a collection of mutations that were 
destructive in terms of gene function, but which occurred in genes that were not 
particularly important for tumor cell survival or competition. These mutations, too, would 
be passenger mutations from a cancer genomics perspective. Realizing the possibility of 
cancer genes experiencing mutations that ought to be classified as passenger mutations 
rather than driver mutations, I became interested in looking at distribution of mutations 
within single-genes. 
These competing selective effects, in addition to other potential confounding 
influences, made the data fairly noisy as a result. There was clearly a positive correlation 
of gene length with mutation counts, but the scatterplot did not pack very tightly around 
the trend line in either population. 
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Figure 24. 100 Genes with highest studentized residuals from each population 
This list was produced by sorting the resulting table of genes with studentized residuals 
produced from a linear regression. The lengths were a calculated value as described 
in methods, and the counts were produced by the same counting program used 
previously. 
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Discussion 
In terms of the mutation types, there did appear to be some significant differences. 
Some specific types of mutations did not pass significance tests such as the proportions 
of C_A|G_T and A_C|T_G, and A_C, C_A, G_A, G_T, T_G proportions individually, and 
the sum of all transitions as well as the non-proportional counts of the C_G|G_C mutations 
and the C_G mutations individually (while G_C with a p value of 0.0487 just barely 
passed), but most did, even when checking if the proportions were the same. Oddly, the 
p value for G_A proportions was 0.39 while the p value for C_T proportions was much 
lower at 0.002. This was probably the result of a relatively small number of samples within 
the low population that had very few reported mutations in the MAF file, resulting in 0% 
for several categories. Since these categories were fairly high in percentage (between 
20-35%), these zero values may have lowered the mean values of the proportions enough 
to cause a statistical significance between the populations.  
When looking at which genes were affected by mutation, here again there were 
differences. A primary driver of these differences appeared to be gene size, but when 
sorting the lists by mutation counts and looking manually at the gene sizes, and when 
using a linear regression and looking at the genes with the highest residuals there were 
some differences that were not driven purely by gene size. 
Having shown that there were indeed differences an obvious question that follows 
is: “What is causing these differences”? I speculate that there are probably a combination 
of structural, biological, and biochemical mechanisms behind these differences (40,76–
83). In addition to clonal selection, there may be mutational hot spots, such as 
microsatellites within some genes and not others. These genes would be prone to mutate 
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more frequently if a condition causing microsatellite instability were to affect the cell. 
Depending on the mutation or regulatory problem that led to the condition causing 
increased mutation retention, certain types of DNA damage may become harder for the 
cells to detect or to repair leading to a rise in mutations that result from that kind of damage 
(45). In addition to this, expression seems to negatively correlate with mutation rates 
across the genome (76). There is also the expected effect of larger genes being bigger 
targets.  
Other causes might broadly increase all types of mutation, due to affecting 
detection of DNA damage or weakening the ability of the DNA mismatch repair 
mechanism to locate and repair multiple types of damage (67,84–86). 
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Chapter 4 
Kurtosis of mutation locations as a Possible Mutation Survey Method and 
Detailed Analysis of Potentially Interesting Genes 
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Introduction 
I next wanted to determine if the distinction between the two classes of tumors 
based on the number of mutated genes carried within the tumors had an effect on the 
mutations that were within the genes themselves. Were certain mutations within a given 
gene more frequently found in the highly mutated group or the less mutated group? Were 
the mutations more random in the high frequency group while those in the low frequency 
group were more specific? The thinking behind my hypothesis is that mutations that act 
as drivers in driver genes should be enriched in the low mutation group than the high, 
while passenger mutations in driver genes should be relatively enriched in the high 
mutation group.  
An extension of this thinking is that within a specific cancer-associated gene, 
specific mutations that enhance an activity that assists in producing the cancer phenotype 
should exhibit an enrichment in the low mutation group and a diluted frequency in the high 
mutation group.  
 
I expected to see a decrease in specificity of mutations in the high mutation group, 
such that even when oncogenes are mutated in the high mutation group, the correct gain-
of-function mutation would not be hit frequently, and that existing tumors or the pre-tumor 
somatic lineage would instead acquire mutations in oncogenes at non-tumorigenic 
locations. In contrast, inactivating mutations in tumor suppressor genes were far less 
precise than the gain-of-function mutations in oncogenes. Thus a random mutation event 
was far more likely to produce a tumor assisting (inactivating) mutation within a 
suppressor than in an oncogene (assuming the given gene will be hit somewhere along 
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its length), and I expected that this effect would also be borne out if the locations of 
mutations within genes were examined between the two groups. In simple terms, I 
expected no dramatic difference in targeting of mutations to specific sites in tumor 
suppressors between the low and high mutation groups (except that the low mutation 
group may be enriched in nonsense or frameshift mutations relative to the high mutation 
group), but that there would be a significant difference in distribution of mutations in 
oncogenes between the low and high mutation groups with low mutation group showing 
targeting of specific activating mutations and a higher degree of randomness in the high 
mutation group. 
Types of Cancer Driver Genes 
Some cancer driver mutations achieve their effects by shutting down a gene which 
when functionally normal acts against pathways that favor tumor formation or survival. 
These genes with anti-tumor effects are classified as tumor suppressors (31,87). In genes 
with this kind of function one will expect higher mutation rates to result in a broad targeting 
of the gene sequence across all exons in any location where a disabling change can 
occur. There may be peaks in codons that only require a single base change to become 
STOP codons, especially if those require mutations are achievable with the most common 
variety of mutations. Due to the less targeted nature of the cancer contributing changes 
in tumor suppressors as compared to oncogenes, higher mutation rates would favor more 
of these mutations having a possible effect just by chance.  
Other cancer driver mutations result in a functional change in the function/activity 
of a gene. These effects require that the gene still be expressed, but the mutation changes 
the function of the gene in some way that supports tumor survival or helps create the 
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cancer phenotype. These genes which can acquire pro-tumor functional changes are 
classified as oncogenes (31,32,87). Due to the requirement of conversion of proto-
oncogenes to oncogenes being a gain of function mutation, these genes will often exhibit 
a mutational profile with specific locations where point mutations can have an activating 
effect (87,88). Due to the highly specific nature of cancer driving mutations in these genes, 
these genes would not be expected to be particularly enriched in tumors with a mutator 
phenotype, as the chance that a mutation would land outside of the specific activating 
targets that are pro-cancer is considerably larger than that of hitting the right spot with the 
right mutation. 
Assessing the Nature of Mutational Specificity: Kurtosis 
Kurtosis (a word derived from Greek, meaning “curved, arching”) is a statistical 
computation that is usually used to get a numeric value that indicates something about 
the overall shape of a graph (89,90). It and skewness are often used when determining 
whether a collection of data seem to fit a normal distribution or not (91). It is a measure 
of “tailedness” of the probability distribution of a real-valued random variable. A peak at a 
point would not be sufficient to raise kurtosis if a normal distribution surrounded that point. 
A normal distribution with very small standard deviation would still have an excess 
kurtosis of 0 (excess kurtosis is a calculation where the raw kurtosis value for the normal 
distribution, usually 3, is subtracted from the raw kurtosis value). A value is leptokurtotic 
(high kurtosis value) when there is a very strong peak that looks like a pointy spike, and/or 
heavy tails. The opposing situation, platykurtosis, would exist in a distribution where there 
was no pointy peak, and the peak was surrounded by a wide and rounded distribution, or 
in more extreme cases, a very wide and very flat distribution. Mesokurtosis refers to 
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values that are less extreme. Normal distributions are mesokurtotic and have an excess 
kurtosis of 0. A Bernoulli distribution with p=1/2, (a coin flip) has a kurtosis of -2. A discrete 
uniform distribution (dice roll) has a kurtosis that varies according to the number of 
possible values (number of faces on the die). At N=3 the excess kurtosis is -1.5, and it 
approaches -1.2 asymptotically as N increases. 
When dealing with genomic coordinates of mutations within a gene, I was not 
dealing with a direct measure of probability of a single random variable, but those genes 
in which there are specific hot spots could still be expected to produce a higher kurtosis 
value than genes where there are no hot spots and mutations are randomly distributed 
throughout the entire length of the gene. Dr. Yu-Bo Wang suggested trying to use kurtosis 
values due to lack of a more obvious tailor-made method for detecting such differences, 
so I decided to see what resulted from these calculations for the mutated genes in these 
populations of tumors. 
Kurtosis is a measure of the shape of a distribution (89,90). Technically, it is a 
measurement of how weighty the tails of a distribution are, though in practical terms, for 
distributions that have a bulk of their probability at the center of the distribution and that 
are symmetrical, it can also be an indicator of sharpness, or pointy-ness. 
There are three terms that generally describe graphs with different kinds of kurtosis. 
The normal distribution, shown in gray on Figure 25, actually has a true kurtosis value of 
3, but is used to define the concept of excess kurtosis, which subtracts the value of the 
kurtosis of the normal distribution from the true kurtosis, which is what is usually reported 
as kurtosis by various types of software, and is what many kurtosis estimation formulas 
return, and as such the normal distribution is considered to have an excess kurtosis value 
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of 0. When I refer to kurtosis values in the latter parts of this document, I am actually 
referring to excess kurtosis returned by an algorithm.  
Leptokurtic distributions generally have a sharper peak, and heavier tails, such as 
the laplace distribution shown in blue in Figure 25. Platykurtic distributions generally have 
flatter peaks and lighter tails. The raise cosine distribution shown in yellow and the uniform 
distribution shown in orange on Figure 25 are both platykurtic. The raised cosine 
distribution has the typical qualities mentioned, and the uniform distribution has no peak 
at all, and is all tail.  
To explain this point, there is a probability distribution known as a U-quadratic 
distribution, that is a continuous probability distribution over a defined range from a to b. 
The quadratic that describes this distribution would be a U shaped parabola (with a focus 
pointing in the positive direction) that is symmetrical about the midpoint between a and b, 
and has total area under the curve of 1 between a and b. The excess kurtosis for such a 
function is 3/112*(b-a)4. The longer the distance from b to a, the more kurtosis this 
distribution would have, and yet it has no peak in the middle. Kurtosis values for this 
distribution can approach zero for very small a to b intervals, but it will never be negative. 
This does suggest that strongly positive kurtosis values obtained from mutation 
locations across a gene would need to be examined for similar heavy tailed distributions 
without a centralized probability peak. I do not expect that mutation distributions fitting a 
very long and heavy tailed distribution with no peaks in the middle such as this would be 
particularly common.  
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Figure 25. Illustrations of kurtosis shapes.  
Several probability distributions were produced to fit within the same x value ranges (0-
14) to illustrate how kurtosis relates to shape. The blue example is a Laplace distribution 
(Leptokurtic). The gray example is a Normal distribution (Mesokurtic). The yellow 
example is a Raised Cosine distribution (Platykurtic). The orange horizontal flat line is 
a continuous Uniform Distribution (Platykurtic). The green example is a unique 
quadratic distribution (Leptokurtic). Excess kurtosis values are shown in the legend 
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Hypothesis 
Within any cancer driver oncogene, specific activating or gain-of-function 
mutations should be enriched in the low mutation group of tumors while non-specific or 
passenger mutations should be enriched in the high mutation group of tumors. To detect 
this difference, I examined the mutations within specific genes. I expected that within 
oncogenes there are a small number of locations where subtle mutations lead to 
constitutive activation of the resulting protein or other subtle alteration in its structure or 
behavior that leads to a tumorigenic effect. This means that there ought to be a very 
specific set of mutations in oncogenes that are capable of contributing to the cancer 
phenotype within the selected tumor population. I expected therefore to see a very small 
number of locations with high mutation counts in these genes when they present selective 
advantage. 
In contrast, I expected that tumor suppressor genes would show a profile where 
mutations appear throughout the gene at any sites where they can deactivate the function 
of the gene, perhaps with some hot spots where it is easier to create damaging mutations, 
but with less precision than I would expect within oncogenes.  
There is also the effect of the mutation rates to consider. My model is that the 
highly increased rate of mutation in the high mutation group would create possibilities for 
random mutations to occur outside the tumorigenesis process that wouldn’t exist at the 
lower mutation rates in the low mutation group. As a result of this increased rate of 
mutations in the high mutation group, there is an increased possibility of redundantly 
affecting signaling pathways via multiple hits to more easily disabled gene targets in the 
high mutation group instead of requiring a precise hit on a canonically important cancer-
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related gene target. Also, the effect of the enhanced mutation rate would generally cause 
a lot more passenger mutations. Therefore, in the high mutation group I would expect the 
mutation accumulation peaks to be less pronounced in oncogenes, and for the oncogenes 
that were mutated, there would be an increased number of non-tumorigenic mutations, 
which would effectively be passenger mutations, in a significantly increased number of 
samples. In contrast, I expect that there would not be very much difference to the 
spectrum of mutations found in most tumor suppressor genes between the two groups 
except possibly an enrichment of missense or silent mutations in the high mutation group. 
In summary, the mutations found within many genes that require precise mutations 
will likely be found to have more accurate targeting in the low mutation group, and less 
accurate targeting in the high mutation group, while genes that simply require deactivation 
will not experience much difference in the distribution of their mutations between the two 
groups.  
Given that mutations in hot-spots will create peaks at a specific point rather than 
at an “average location”, these would tend to produce a leptokurtic scenario. If there are 
multiple hot spots that are not localized to a particular section of the gene this would trend 
toward producing a mesokurtic result, especially if there are also off target mutations 
spread through the gene, or spanning multiple exons. If the gene has no hot spots and 
no selective locations producing oncogenic traits, and sports very long “tails” of off target 
mutations spread throughout the gene, this would be expected to produce platykurtic 
values. 
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Methods 
For a selected set of oncogenes with known effective mutation sites and a set of 
suppressor genes, I examined the mutation locations that appeared within the two sample 
groups. Counts were tallied per genomic location, and these counts were used in 
conjunction with annotations of known effective sites to test the hypothesis. 
I sought advice on how to discriminate between mutation profiles containing strong 
peaks and mutation profiles with wide dispersal of mutations from statistics experts Drs. 
James Grady and Yu-Bo Wang. Yu-Bo suggested that I try computing the kurtosis of the 
genomic positions, and see if the kurtosis values signaled the position of strong peaks. 
Based on my observation of some of the mutations lists and the resulting kurtosis values 
this method has resulted in at least a partial success, although there are some caveats 
to the method. Some distributions that have no peaks result in kurtosis values that 
suggest there should be strong peaks. It did produce some interesting and potentially 
useful results though. 
I accomplished the kurtosis calculations using a python program to control function 
calls in R using a module called rpy2. The kurtosis function from the R package e1071 
was used. A list of start positions for each mutation within each gene was compiled, and 
this list of numbers was fed to the kurtosis function. The resulting numbers were compiled 
into a tab separated table as output. 
For a selected set of genes, I pulled a list of the mutations out of the MAF file using 
command line tools. I queried for the lines containing the requested gene symbol and 
pulled out the relevant fields for the start and end locations. This was sorted and 
duplicates were counted, producing a set of tables showing the number of mutations at 
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each position. For better comparison between the high and low mutation groups, I added 
columns that divided the count values by the tumor population size. 
Results 
As expected, mutations in oncogenes showed a strong preference for specific sites 
to a much higher degree than the mutations in tumor suppressors within the low mutation 
population. The high mutation population showed a higher degree of randomness and 
significantly less specificity. However, the results were not completely clean. In both the 
low and high mutation groups, tumor suppressor genes still showed statistical 
preferences for some sites. It is possible that this preference might have been due to 
ease of mutational deactivation at these sites by creating premature stop codons or 
significantly disrupting the action of the gene by disrupting normal folding or structural 
integrity of the peptide at these enriched sites.  
An exception to the higher degree of randomness in the mutations in the high 
mutation group was found for the gene BRAF. This decreased randomness was 
consistent with the previous observation that specific mutations in BRAF were associated 
with and advantageous to the mutator phenotype (92–94). Thus I confirmed the possibility 
of there being some exceptions to my hypothesis on a genome-wide basis if certain 
mutations within specific oncogenes are strongly selective within the mutator phenotype. 
Vogelstein et al. composed a list of cancer related genes classified as tumor 
suppressor genes and oncogenes according to a scoring algorithm (31). I wanted to see 
the mutation profiles of these genes and whether the kurtosis values for these genes 
obeyed my model based on their Vogelstein classification. I found that the kurtosis values 
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were consistent with my model for both tumor suppressors and oncogenes and between 
the low and high mutation frequency populations. 
APC, short for Adenomatous polyposis coli, is a well-known tumor suppressor 
gene that has been found to have very prominent involvement in colon cancer (95), and 
was given a name based on that relationship. APC had high kurtosis values in both 
populations, with a very strong value for the high population. This was not unexpected, 
given that destructive mutations often cluster in important functional motifs, and due to 
the very strong association of this gene with colon cancer. The increase in kurtosis in the 
high mutation group could be due merely to the very high mutation rate, or might be the 
result of random fluctuation in the locations where the mutations hit. Perhaps the gene 
has hot spots for mutation that are more likely to mutate under the conditions present in 
a cell with a mutator phenotype. 
BRAF an oncogene with known association to tumors with DNA repair disorders, 
(92,94) had very high kurtosis in the high mutation group, an expected result in this 
population.  
KRAS does not share an association with mutator phenotypes or DNA repair 
disorders (96–98). It had high kurtosis in the low mutation group, showing very strong 
selection for the oncogenic mutation locations. In contrast, KRAS was rarely mutated at 
the oncogenic sites in the high mutation group.  
Compared purely in terms of accumulated mutation count, APC had 84 mutations 
in a population of 180 tumors in the low group (0.46 mutations/sample), and 15 mutations 
out of a population of 39 (0.38 mutations/sample), but to focus on this alone would have 
missed a very important aspect of how oncogenes like KRAS mutate. KRAS only 
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experiences oncogenic mutations as a result of specific changes at specific locations in 
its sequence.  
Position chr12:25398284 (in GRCh37/hg19), corresponding to the 2nd base in the 
12th codon of KRAS, was the most mutated site, with 39 mutations. The codon at this site 
is usually GGU (Glycine). There were 3 mutation variants found at this site. C to T (19 
counts), changes the codon to GAU (Aspartic acid). C to A (15 counts), changes the 
mRNA codon to GUU (Valine). C to G (5 counts), changes this codon to GCU (Alanine). 
A site immediately adjacent at position chr12:25398285 which is the 1st base within the 
same codon, had 11 mutations. C to T (5 counts) results in codon AGU (Arginine). C to 
A (4 counts) results in codon UGU (Cysteine). C to G (2 counts) results in codon CGU 
(Serine). 
Another site, at position chr12:25398281 corresponds to the 2nd base in the 13th 
codon which is usually GGC. This C to T mutation (16 counts) results in GAC (Aspartic 
acid). The first base of this codon also experienced a C to A mutation to produce a UGC 
codon (cysteine) in one sample. 
It is unclear whether all of these amino acid changes result in an oncogenic protein. 
Changes to codon 12 and 13 tend to be oncogenic (98,99), but mutations other known 
locations were not particularly common in this type of tumor. 
Limitations of the analysis 
Kurtosis appeared to function well as a positive identifier, but its power in terms of 
negative results was unreliable due to the relatively low mutation counts some genes 
experience and the fact that some genes’ involvement in cancer is related to the tissue of 
origin, and that some genes might exhibit a very platykurtic distribution if they are tumor 
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suppressors lacking hot spots. Thus its utility in identifying interesting genes lies solely in 
comparative results (which group shows a higher value) and even so requires more 
detailed follow-up analysis to interpret any positive results. It therefore can serve as a 
useful flag for taking a further look at genes that show high kurtosis values.  
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Figure 26. Kurtosis values for Vogelstein Subtly Mutated Gene List for TCGA data. 
Genes that were found in the supplemental data of the 2013 Vogelstein paper on 
Genomic Landscapes in Cancer (31) but which had no counts or not enough counts to 
be able to compute kurtosis for either population were omitted from this table. The table 
was sorted by the Vogelstein classification first, and as a secondary sorting rule the 
genes with higher values in the LOW population than the HIGH population were sorted 
toward the top. 
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Examining Outliers and Potentially Interesting Genes in More Detail 
I examined a subset of genes that seemed particularly out of place in regard to 
their size vs their mutation counts. I included a calculation for the absolute value of the 
difference for the kurtosis value between the groups and sorted according to that 
difference. My hope was the genes with the most different values would have significant 
shifts in their mutation distribution, and perhaps would have a functional association with 
cancer phenotypes. They might also have targeted locations that mutate and become 
strongly positively selected. I included TTN on this list because despite its massive size, 
it had many more mutations than its size ought to dictate based on the general trend, and 
it is also a very good example of a gene that was computed to have low kurtosis on its 
mutation locations, and actually deserves the negative result. The mutations in TTN do 
not pile up at any particular spots. The mutations are spread out quite a bit, with all of the 
locations only having 1 or 2 mutations, with counts of 2 being infrequent. Due to this very 
spread out and sparse mutation pattern, I opted not to show TTN’s mutation locations in 
detail. 
In Figure 27, I highlighted in green those genes that were also contained within the 
Vogelstein list of oncogenes and tumor suppressor genes known to be associated with 
cancer phenotypes (31). Their results may also help in understanding these mutation 
profiles and how the mutation rates affect them. There are clearly some genes with very 
strong kurtosis values, and also some genes that only pile up enough to get positive 
kurtosis in one group or the other. Interestingly, a good number of the genes showed a 
higher degree of “pointiness”, as scored by kurtosis, in the high mutation group, where 
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one would usually expect an increase in randomness. These genes may provide a benefit 
of some kind to mutator phenotypes when mutated. 
The first table contains those genes which had a positive kurtosis in one group and 
negative kurtosis in the other. The second table was produced from the remaining genes. 
Kurtosis could not be computed for TPRX1 in the high group, so I left it in the second list. 
SOX9 is a good example of a gene where the kurtosis is higher on one side, but 
for which additional information is required to determine if this corresponds to a 
meaningful difference in mutation location or is a result of random differences. There are 
more mutations in the low population (25) than in the high population (7), which could 
lead to there being more mutations in a similar region merely due to the difference in size 
between the populations. The mutations don’t pile up at a single location, but since SOX9 
acts a tumor suppressor gene (100,101), this is not surprising. They may still be piling up 
within protein domains where a disruption is more likely to destroy the function of the 
gene, and this might lead to a relatively higher kurtosis when there are more mutations to 
use in computation. 
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Figure 27. Kurtosis Values for selected genes from linear regression table. 
I picked a number of genes with relatively smaller sizes from the residual-sorted tables 
This table was sorted to place the values which were negative on one side and positive 
on the other first. These values were placed into the first table. The rest were placed 
into the second table. The genes were then sorted by the absolute value of the 
difference in kurtosis between the high and low groups. Two dashes signify that kurtosis 
could not be calculated for that gene in that population. Genes from the Vogelstein list 
(31) are highlighted in green. 
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The cancer gene list (31), as a whole, contained genes that were not necessarily 
expected to be associated with colon cancer, and thus resulted in many genes having 
low kurtosis in both groups. It was interesting that so many genes had higher kurtosis for 
the HIGH mutation group, where I generally expected more randomness. I then decided 
to take a look at the genes canonically associated with colon cancer. 
I compiled a table (shown in Figure 28) based on the list of mutations and genes 
on mycancergenome.org (102). While it is a complex table, I structured it such that only 
known mutations would be counted. It would show a dash for any value that was not 
defined in the known mutation part of the table. 
As mentioned previously, KRAS showed a strong preference for mutations in 
codon 12 and 13, and to a lesser extent, codons 61 and 146, while other locations were 
rarely mutated.  
In BRAF there was strong tendency for changing codon 600 to code for Valine. 
This BRAF mutation is highly associated with defects in DNA repair (92,93,96). This 
targeting of the mutation to a specific location (V600E) was captured quite readily by the 
difference in kurtosis. 
PIK3CA is strongly associated with colon cancer (103,104) and showed a strong 
tendency for mutation at codon 545, changing from Glycine to Lysine. There was a 
concordant rise in kurtosis, but the number of off target mutations (and perhaps their 
distance from this mutation peak), was sufficient to cause the resulting kurtosis to be 
somewhat low. This is why the change in value between the same gene in both 
populations is more important than the actual value of the kurtosis. 
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PTEN is another gene associated with microsatellite-stable colon cancer (104,105). 
Its mutation spectrum was particularly interesting. It showed NONE of the three known 
cancer-associated mutations (102), though one was very similar (there was a deletion 
mutation at a position very close to the listed one found in both populations). There were 
also a few other frame shift mutations at different locations and some nonsense mutations 
as well. These could possibly all be oncogenic due to destroying the function of the 
resulting PTEN protein or initiating nonsense-mediated decay (106) and resulting in no 
protein being made at all. 
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Figure 28. Genes known to be associated with colon adenocarcinoma (102), their 
known mutations, and their kurtosis values in the high and low mutation populations. 
The first table lists genomic position, codon number, CDS position, reference base, 
original amino acid, the resulting amino acid for known mutations, and counts of 
specified mutations within the high and low mutation groups. 
Of the smaller tables, the one on the left shows counts of known mutations the total 
number of mutations for that gene and a ratio of known mutations to total mutations. 
The smaller table on the right shows the kurtosis values for these genes. (-- is a stand 
in for a value that was unable to be computed due to there not being enough mutations) 
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The Table in Figure 28 demonstrates a key point about the differences between 
tumor suppressor genes and oncogenes. For the tumor suppressor genes, as long as 
their function is diminished or destroyed, the mutation can be assumed to contribute to 
oncogenesis. For oncogenes, a gain of function is required. Thus, in most cases, for 
oncogenes, nonsense mutations and frameshifts, while certainly destructive to gene 
function, will not likely contribute to oncogenesis. Mutations involving the splice site and 
an in-frame insertion or deletion are also more likely to be non-oncogenic in these genes, 
depending on their effects. Silent mutations would be expected to be ineffective in both 
types of genes. Thus, using algorithms that determine disruptiveness of the mutation 
and/or the ontology of the gene where a mutation occurs as the determinant for whether 
the mutation is expected to be pathogenic in terms of cancer, would be a mistake if one 
does not take into account what sort of mutation would actually produce an oncogenic 
outcome. 
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Figure 29. COAD Mutations Classified by types  
Missense mutations change the amino acid. silent mutations result in the same amino acid. Nonsense mutations result in 
a stop codon. Frame shifts resulting from insertion or deletion are shown, as well as in-frame deletions and insertions. 
Mutations involving the splice site are counted as well. Subtotals for the low and high groups as well as an overall total 
are at the bottom. 
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The genes in Figure 30 were of particular interest. BRAF, EGFR, HRAS, KRAS, 
RB1, and TP53 are on this list due to being known for bearing canonical cancer driver 
mutations. TTN was an example of a gene that was not expected to have any specific 
mutations related to cancer. KRTAP4-3 (107,108), KRTAP4-5 (107,109) FAM194B 
(110,111) (which has had its official symbol changed to ERICH6B), and DSPP (112–114) 
were mutation count trend outliers that looked to have potentially interesting mutation 
distributions. 
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Figure 30. Selected Genes of Interest 
Counts were obtained from the same program as used previously. Kurtosis values were 
obtained using R as described in methods. 
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KRAS had three heavily targeted mutation locations within the TCGA dataset 
which are known sites (98,102), one of which is the most frequent (Figures 29 and 33). 
BRAF has one specific oncogenic mutation site (92,93,96) (Figure 31). In both of these 
genes the oncogenic sites were found to be hit at these sites much more frequently than 
any other locations. KRAS had a strong preference for its oncogenic site in the low 
mutation population, but this preference significantly diminishes in the high mutation 
population. BRAF shows the opposite. It barely showed any mutations within the low 
mutation group and had very high rate of mutation at its oncogenic target in the high 
mutation population. BRAF has a known association with tumors that exhibit DNA 
mismatch repair defects (92–94,96), so these results are expected. It is interesting that 
oncogenic KRAS had such a strongly diminished representation within the high mutation 
population of tumors. KRAS followed my expectation for oncogenes, but BRAF, due to its 
association and apparent selective effects within that population, actually followed the 
opposite pattern from my expectation. It did however still have a very strong kurtosis in 
its associated population, due to the strongly targeted mutation. 
TP53 is also associated with colon cancer (53,115–117) and had several peaks, 
but it also had a great many mutations throughout its sequence (Figure 31). In that respect, 
it follows my expectation for tumor suppressors. It does not follow my expectation in 
respect to mutation frequency between the two populations. In the high mutation 
population, the representation of TP53 mutations drops by about 50%. In the low mutation 
population containing 180 tumors, there were 117 mutations in TP53 (0.65 
mutations/sample), where in the high mutation population of 39 tumors, there were only 
13 mutations in TP53 (0.33 mutations/sample). This was consistent with previous reports 
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that colon tumors with microsatellite instability due to mutations in MMR genes are less 
likely to have mutations in either KRAS or TP53 (72).  
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Figure 31. Known Cancer Related Genes 
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is on chromosome 12 (118). 
BRAF (B-Raf Proto-Oncogene, Serine/Threonine kinase) is on chromosome 7 (119). 
TP53 (Transformation-Related Protein 53) is on chromosome 17(120). 
Start and End columns refer to the genomic locations of the mutations. 
Count column refers to the number of mutations found at the coordinates. 
The Normalized columns were produced by dividing the counts by the sample 
population size of each group (39 for the HIGH group, and 180 for the low group). 
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Both KRTAP4 genes (107–109) seemed to have a strong mutation peak in the low 
group at a single location (data shown in Figure 32). KRTAP4-5 also had some mutations 
at 3 other locations that might be selective, with 8, 4, and 6 mutations each. These 
mutations are relatively close to each other, and might affect the same structure or protein 
domain. At least one other keratin associated protein has been found to be involved in 
cancer (KRTAP5-5 (121)). KRTAP4-3 has 47 references listed on its COSMIC (Catalogue 
Of Somatic Mutations In Cancer) page, and KRTAP4-5 has 53. However, it is reasonable 
to be suspicious of these genes as possible drivers or contributing in some meaningful 
way to the cancer phenotype. Both KRTAP genes result in fairly small transcripts (879 for 
KRTAP4-5 and 942 for KRTAP4-3). Neither appeared to be mutated as broadly as TP53 
or DSPP. Despite the presence of mutational peaks, these genes were not quite as 
preferentially mutated in either population as KRAS and BRAF. They had a prominent 
kurtosis in the low population, and not so much in the high population. The profile 
appeared to follow my expectations for an oncogene in respect to their mutation peaks, 
but they did show significant numbers of mutations at off target sites, which was more 
similar to my expectations of tumor suppressors. Thus, whether or not my predictions for 
the behavior of those tumor gene classifications turns out to be correct, they do appear 
to be worth treating as candidate driver genes. 
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Figure 32. Two keratin associated proteins found on chromosome 17 that were 
adjacent to each other (107–109), and similar in size. Columns are the same as in 
Figure 31. 
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ERICH6B, formerly called FAM194B, has been reported as mutated in cancers 
(110). Its COSMIC entry (which is still under its older name FAM194B), has 62 entries in 
its references list. It showed a very targeted set of mutation peaks within a small genomic 
region (data shown in Figure 33). These were about 11 bp in size, with 4 locations being 
targets. There were not very many mutations within this gene outside of the targeted 
location. It also seemed to be mutated at these targets to a proportionally larger degree 
in the high mutation group. Its locus spans 81218 bases, but its exonic size is fairly small 
containing ~2421 bases and resulting in a protein 696 amino acids in size. The profile 
does seem to be more similar to a tumor suppressor than to my expectations for an 
oncogene, but it is hard to use my model to suggest which classification this gene might 
fit. The relative lack of mutations throughout the gene could simply be a function of how 
small the spliced transcript is. The range of the mutation target suggests that the mutation 
may be disrupting a structure in that area or a function that relies on that 11 bp region. 
That domain might become inactivated due to these mutations, but I do not know how 
that impacts the function of the gene as a whole. It still presents itself as an interesting 
driver gene candidate. 
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Figure 33. ERICH6B / FAM194B. This gene, from chromosome 13, is named 
ERICH6B. It was named FAM194B within the MAF file obtained from TCGA due to the 
older annotation data the project used. The name has since been changed. The new 
name stands for Glutamate rich 6B, while the old name stood for family with sequence 
similarity 194, member B. Columns are the same as in Figure 31. 
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ZNF814 is a gene found on chromosome 19. It has a generic name based on its 
high number of zinc finger motifs, and not much appears to be known about it. A ten base 
pair region showed a high concentration of mutations in both groups, with 3 additional 
locations relatively close to that region also showing involvement. It is unknown what 
affect disrupting this region of the gene will do, but it does appear potentially interesting 
as a candidate driver gene deserving further research. 
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Figure 34. ZNF814. This gene is located on chromosome 19. “ZNF” is an 
abbreviation of “zinc finger”, a type of motif that this gene contains in several locations. 
Columns are the same as in Figure 31. 
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DSPP has also been associated with cancer in previous work (113,122). There are 
93 entries in its COSMIC references page indicating it may have some involvement in 
cancer. DSPP had a higher kurtosis value in the high mutation group. It showed a peak 
of mutations in a 12 bp region targeting 4 locations (data shown in Figure 35). There was 
also another peak that showed up within the low population 621 bp away from the other 
cluster of mutations. This population lacked a peak at the second location, which might 
be partly responsible. It demonstrated preferred sites, but the peaks were pretty 
consistent within the high group and there were a lot of off target mutation locations all 
through the gene as well. Its mutation profile superficially resembled that of TP53.  
There were some targeted locations, but these were mostly silent mutations, and 
there were also a very large number of mutation peak locations all through the gene. Thus 
the fairly wide spread of mutation locations indicated that I should expect the gene to act 
as a tumor suppressor if it has any involvement in cancer, but it turns out that a large 
number of these mutations were silent. Due to the mutations mostly being silent, the gene 
is less promising as a candidate driver gene, but it does deserve a deeper look given that 
it has some degree of mutation frequency other than the mutation count peaks. 
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Figure 35. DSPP (Dentin sialophosphoprotein) is found on chromosome 4 (112). 
Columns are the same as in Figure 31. 
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TP53, DSPP, ERICH6B, KRTAP4-3, and KRTAP4-5 were all found to be mutated 
more often than their size should dictate, and have mutation patterns suggesting there is 
a selective effect at some of these loci in tumors within the colon TCGA sample set. These 
genes have also been previously reported in lists of affected genes or in cancer studies 
previously. Many of the mentions involving these genes have been the result of genome 
wide association studies in large lists of results as opposed to specific research into these 
genes to characterize their function and possible contribution to cancer phenotypes. 
Discussion 
In summary, I found that some genes had differences in their mutation distribution 
pattern between these groups. The kurtosis values as a survey method do appear to be 
somewhat useful, but require careful analysis to interpret. My hypothesis regarding 
targeted mutations concentrating the in the low mutation group did not hold for all genes, 
but in the broad sense the expectation was still valid. Some of the genes known to be 
associated with colon adenocarcinoma possessed many mutations in known locations, 
however genes such as PTEN did not mutate in known locations at all and as predicted 
by my model, there were more passenger mutations in several of the genes that I 
examined closely in the high mutation group than there were in the low mutation group. 
At least one gene, BRAF, had its targeted mutations concentrated in the high mutation 
group, presumably because they offer these tumors some kind of selective benefit, and 
either do not affect other types of tumors or present a selective detriment.  
 139 
 
Alternative approaches  
A more ideal method would be to develop a sophisticated bioinformatics model to 
carry out this analysis. A statistical test for each site or for groupings of sites (if there are 
multiple effective spots, vs useless spots in the case of oncogenes) could be programmed, 
and each gene would require a designation as an oncogene (with an associated list of 
effective mutation sites, and types of mutations that are known achieve the tumor driving 
effects), or as a tumor suppressor, or a passenger (reasonable to conclude as uninvolved 
with tumor phenotype) or an unknown status (where not enough is known about a gene 
to make a determination). From there it could analyze the patterns of mutations found 
within the gene against expectation values to produce an ability to cluster samples 
according to similarity of mutation patterns, or even perhaps to set up a neural network 
to recognize these patterns in future data sets.  
Once the profiles of these genes are better understood, a similar algorithm could 
be engineered to use these types of profiles to predict if a candidate gene is likely an 
oncogene or a suppressor, based on the distribution of mutations within population splits 
based on total mutation count in large datasets. A potential confounding factor is how to 
differentiate preferred sites based on deactivation from those that are activating mutations. 
The number of such sites within a gene tends to be much smaller for oncogenes, so the 
probability could be assumed to be inversely correlated with the number of codons 
affected, though genes with complicated folding pattern, or that participate in multi-protein 
complexes could have multiple locations throughout their sequences that participate in 
important enzymatic activities, ability of the protein to recognize and bind to substrates, 
influence folding and structure, or even influence the protein’s ability to bind to a 
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multiprotein complex. My method of using kurtosis over the full set of mutation locations 
might be unable to properly signal peaks in genes where these preferred sites are more 
distant from one another. Perhaps a different statistic would be better, and perhaps 
computing kurtosis, or a more specialized statistic, using a sliding window of some 
number of nucleotides might prove to be a more powerful application of this idea to identify 
locations where there is a mutation peak. This is an important improvement to seek, 
because there may be cases where a range of nucleotides within a protein domain could 
be modified and achieve similar effects rather than just a single location of small handful 
of locations. For example, a gene that promotes cell survival or growth might be converted 
to being more active by blocking the binding of an inhibitor by changing its binding site 
via mutation. This could possibly be achieved by changing multiple nucleotides in the 
sequence of its binding domain, while retaining the overall structure of the protein and 
preserving its ability to carry out its biological activity. In such a case there wouldn’t just 
be one peak, but rather a generally raised mutation rate over a wider genomic region. 
Whether kurtosis calculations would pick up on this pattern would depend partly on the 
size of the domain, how spread out the mutation sites are, and on the number and location 
of any passenger mutations exist in the population being studied, but perhaps a more 
sophisticated statistical model would be more sensitive and able to pick up on such a 
pattern more easily. 
If protein structure data is available, perhaps the 3-dimensional distance between 
different amino acids and their associated codons could be used to determine if clusters 
of mutation peaks at different locations within the transcript are affecting the same relative 
physical location in a folded protein structure. Structure based algorithms would be 
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significantly more complex than simple sequence analysis, but could prove fruitful. 
Unfortunately, this would require data that is not always available for genes of interest, 
and would require an analytical method requiring a highly complex model and algorithm 
that is not currently available.  
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Chapter 5 
Technical Difficulties Encountered During the Analysis 
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Technical Difficulties Encountered During the Analysis 
Database Issues 
There were some issues that I encountered during this project that were related to 
the way that the data was collected and formatted in the mutation database. When I was 
performing the length and mutation count analysis in chapter 3, I had to obtain gene 
lengths to use. I decided to use the transcript length since the MAF files did not include 
mutations in intronic regions. For genes with multiple transcript lengths I opted for a simple 
average. Since the MAF file was not making transcript distinctions, I would have had to 
obtain and parse through a list of alternatively spliced genes and their exon locations. 
This would have complicated the analysis quite a bit, and for a gain in accuracy that did 
not seem to be very significant.  
I used the UCSC table browser to pull down a table containing the information I 
was looking for. However, when I tried to relate the information in the MAF files to the 
information in the gene tables from UCSC I quickly noticed that there was a problem. The 
gene symbols did not match for a number of the genes from the TCGA project. There had 
been changes to quite a few of them. I used a combination of methods including checking 
the current ID for the ENTREZ ID in the MAF file and checking databases of gene symbols 
for previous and new names. To parse all of this output, I tagged on an Updated Symbols 
column to the table. After doing this I was able to perform the length collection, and 
averaging where necessary. 
This would have been made significantly easier if there were a TSV file available 
that I could have parsed through for old symbols and new symbols, but due to having to 
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cover for weaknesses and missed genes in each approach, it became a bit more difficult 
than it ought to have been. 
Problems with the COSMIC database 
I had looked at the COSMIC (Catalogue Of Somatic Mutations In Cancer) 
database, and noticed that there was a pair of columns in the table that included FATHMM 
score and FATHMM prediction. I looked up the FATHMM software, and its webpage 
states that it uses Hidden Markov models to score the probability that single nucleotide 
coding and noncoding variants have functional consequences. It has options for inherited 
diseases, cancer, and other disease specific options. 
Intrigued by this, I set about writing a program to match up the entries from the 
MAF file to the COSMIC database. A few things became apparent fairly quickly. The first 
was that again, the gene symbols were not matching up, as had been the problem in 
pulling the transcript lengths out of the genome database table. I used a similar solution 
for the COSMIC file as I had used with the lengths. The next was ensuring that I was 
matching up the correct mutation. The COSMIC database encodes its mutations in CDS 
format. This format proved quite frustrating to read using programmed parsing, and 
eventually I gave up trying in favor of another choice. I noticed that the VCF format 
COSMIC files encoded the genomic location, in addition to the from and to nucleotide 
sequence changes.  
Due to a few quirks of the VCF format, I had to work out some minor mismatches 
(under certain circumstances this format includes leading sequence homology of at least 
1 base, and adjusts the sequences displayed and the indexes accordingly). It was still far 
simpler to do this text manipulation and simple math than to match up the CDS formatting. 
 145 
 
To my disappointment, I found that the FATHMM results appeared to be purely structural. 
As an example, destructive mutations in known oncogenes were still being scored as 
pathogenic, rendering the results significantly less useful than they could have been. 
There were also cases of multiple entries for the same genomic location with the 
same mutation. The COSMIC database is in need of some periodic manual or automated 
curation to identify entries that ought to be merged. Perhaps there is a reason these 
entries are being kept separated, such as being from tumors of different tissue origin, 
despite being the same mutation. I am not aware of what justifications there may be, only 
that it is not something that I had expected to find in such a large, ostensibly important 
database for genomic research. It would also be nice if they added additional columns 
that contained genomic coordinates and the “FROM” and “TO” DNA base characters 
rather than requiring that one decipher the CDS string or read the VCF files. 
As a consequence of these technical problems, I chose not to pursue this line of 
analysis any further. Recall the classifications of tumorigenic genes that Vogelstein et. al 
produced. Some genes were classified as tumor suppressors, and would be expected to 
become tumorigenic via any disabling mutations, while others, called oncogenes, 
required specific activating mutations to become tumorigenic. One possible way to 
approach this problem with COSMIC classifications might be to try to use the Vogelstein 
classifications and the COSMIC predictions together to come up with a merged result. 
The problem in attempting to do this is that the one would need a list of gain-of-function 
mutations for each oncogene in order to know the difference between the destructive 
mutations and the gain-of-function mutations.  
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What might actually be better than trying to merge these results would be a more 
strictly curated sub-database specifically dedicated to tracking known functional 
mutations in cancer instead of all reported mutations. A database that could track the 
class of cancer gene would help in making predictions of mutation consequence more 
accurate and more comprehensive. This database could also usefully curate the 
classification of the mutation’s effects, such as specifying gain-of-function, loss-of-
function, loss of ability to respond to regulatory signals, loss of critical protein domains or 
other types of protein truncation, etc. 
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Chapter 6 
Future Directions and Conclusion 
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Implications and Future Directions 
In this last chapter, I would like to describe some future directions in which my 
thesis work could be extended. These include both novel analytical and functional 
avenues to examine the notion of differential targeting of genes based on mutation 
frequency in the individual tumors.  
Obtain access to the rest of the Samples, and Germline data, and use SOLiD sequencing 
results 
There were 54 samples in a separate MAF file that resulted from SOLiD 
sequencing. I did not think the benefit of the small increase in numbers would warrant the 
possible confounding influence by including these results so I did not utilize this file in this 
analysis. However, according to the GDC data portal there are now 463 colon tumor 
samples in the database. When I originally pulled the available data from the portal that 
the TCGA project had previously made available, data from some of these samples were 
not included. Perhaps analysis had not been completed on all of the samples, or perhaps 
not all of the samples were made publicly available without a security agreement at the 
time. Regardless of the reason, data from 193 samples was unavailable. In addition, none 
of the germline data was available to me, since neither I nor the UCHC had gone through 
the security agreement process in order to assure the TCGA that I will be able to adhere 
to minimum security requirements. The data for 458 of the samples, including the samples 
that were previously missing, has now become available from the GDC portal.  
Before proceeding into other tissue types, the obvious follow-up to my work would 
be to go through the required steps to gain access to the germline mutations and to 
include these in the analysis. Additionally, the location of the mutation data for the 
 149 
 
remaining 193 samples should be included. The germline mutations, when combined with 
expression data also available in the database, would give clues as to which samples 
were the result of heritable conditions like Lynch Syndrome or of sporadic mutation or 
repression of known repair genes. There are also 172 cases of rectal cancer with sample 
data in the database, of which 158 samples have nucleotide variation data available, that 
could reasonably be combined into an analysis of colorectal cancer as a whole. 
Extend analysis into other tumor types typically associated with either MMR or other kinds 
of genomic instability. 
A very common cause of tumors with very high mutation rates is a defect in one of 
the genes that contributes to the DNA mismatch repair (MMR) pathway. Heritable 
mutations in these genes lead to a condition known as hereditary nonpolyposis colorectal 
cancer, or Lynch Syndrome. Somatic defects in these genes, including mutations and 
aberrant epigenetic silencing, also occur. 
Tumors of this type occur most commonly in colon and rectal tissue, but the 
heritable conditions also cause a significant rise in tumors of other tissue types, which 
would also have a chance of suffering sporadic mutations producing the same mutation 
rate increasing condition. Expanding this analysis to include other tissue types might be 
beneficial as it could help reveal the impact of tissue specificity of certain tumor genes, 
and would also increase the number of samples significantly. The obvious first choice 
would be to include the rectal tumor samples. With the larger dataset it would become 
more feasible to see if the raised mutation rate tumors all have the same mutation profile, 
or whether there are subtypes within the category. One possible distinction would be 
tumors with defects in MMR vs those that have a large number of mutations despite an 
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apparent lack of defect in the MMR system. Classifying tumors this way would require 
access to the germline mutation data to detect Lynch Syndrome, and would also require 
scanning the expression data for the genes known to play a part in the mismatch repair 
system. The colon tumors are already characterized in terms of microsatellite stability, 
which is another diagnostic clue, but it is possible that not all of the other tumors would 
have the results of such analysis included in their clinical data files. 
Other tumors have been associated with Lynch Syndrome including gastric cancer, 
endometrial and ovarian cancer, prostate cancer, hepatocellular cancer, pancreatic 
cancer, urinary tract cancers, kidney and bile duct cancers and brain tumors. It would be 
interesting to compare the frequency and patterns of mutations in these other Lynch 
Syndrome-related tumors to the mutations that were found in the colon tumors. It is likely 
that the same pattern of high and low frequency mutations would be detected in these 
tumors and that like the colon tumors, there would be differences in the types of genes 
that are altered in the high and low frequency mutation tumors. It would be interesting to 
compare the mutations between these tumors and the colon tumors to see if MMR-related 
tumors show preferences for types of genes that are mutated. It would also be interesting 
to compare the types of genes mutated in the tumors with low numbers of mutations to 
see what common pathways occur in the non-MMR-related examples of these tumors. 
This would potentially be a way to discover common driver mutations that are associated 
with sporadic forms of these tumors.  
Extend analysis into other tumor types not typically associated with MMR 
Finally, it would also be interesting to look at cancers that are outside of the Lynch 
Syndrome cluster of tumors. Lung cancer, breast cancer, as well as the soft tissue and 
 151 
 
bony sarcomas typically are not associated with Lynch Syndrome or mutations in the 
MMR pathway. An analysis of these tumors would be interesting both to see if there are 
differences in the frequency of mutations within the tumor samples for a particular cancer 
and whether those tumors would also show a difference in the types of genes that are 
mutated in the high and low frequency mutation groups.  
Replace kurtosis with a more accurate scoring model 
While kurtosis did turn out to be somewhat useful, it is also apparent that it has 
strong weaknesses. It is liable to being confounded by spread out mutations and multiple 
independent hot spots. While it could possibly detect clustering of mutations within a 
protein domain, this is both a good and a bad thing. It would be more ideal if I could 
differentiate what was contributing to the score. Peaks within specific codons and 
mutations clustering within a small genomic region are different phenomena that would 
be useful to identify. 
As such, it would be ideal to construct a set of bioinformatics models to use for 
scoring these mutations that would identify these different conditions. Different models 
for detecting domain preference and specific codon preference would be needed. Use 
ontology data and known mutation information where appropriate and available. Ideally 
one would include gene ontology and classifications like whether a gene was an 
oncogene, tumor suppressor gene, or of unknown status, in the analysis of mutations. 
Then I could replace kurtosis with these scoring algorithms and gain a much more useful 
and specific result.  
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Try to develop self-clustering methods based on mutation patterns 
Early on in this project I became interested in the potential application of self-
directed clustering on these mutation patterns. One key problem is that most clustering 
algorithms depend on numerical distance scores, and much of the mutation data is 
Boolean in the sense of whether a mutation has occurred within a designated region, or 
with a matching base change if one got specific enough. Different models for scoring 
mutations between any two samples or any grouped set of samples and another sample 
could be developed that calculate distance values based on this information. One part of 
the algorithm could look at the mutation patterns in terms of the chemistry of which bases 
are changing to which other bases, and another module could examine for selective 
genes using information about the codons, known cancer mutations, and gene ontology 
and systems biology pathway information. This could aid in discovering patterns in the 
data that would be difficult to manually expose, and that might have biological or clinical 
significance.  
Identify new driver genes based on outlier status in the analysis 
One potential future extension of this analysis and expansions of it into other 
tissues, would be to use the results of this analysis in an effort to identify new tumor driver 
genes from the positively deviating outliers in the mutation versus length analysis. The 
kurtosis values or a replacement scoring algorithm might also provide additional clues in 
terms of identifying genes with mutational hot spots that may prove to be interesting 
candidates. 
When these mutations at specific sites are identified as statistically common, one 
could then induce or engineer cell lines to have the same mutations and examine what 
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effects these mutations have on cell phenotype, regulatory pathways, and expression 
patterns. 
Examine differences between selected genes and mutation incidence. 
One of the potentially most interesting applications of this work might be to 
examine the differences between potential driver and passenger genes and the mutation 
incidence over time. Dr. Richard Lenski has been working on an ongoing long-term 
evolution experiment in E. coli (123). This project, that began in 1988, involves keeping 
12 populations of E. coli bacteria in continuous culture, storing samples of the strains at 
regular intervals, and examining their genomes for mutations and changes in genotype 
frequency over time. These 12 populations were initially the same strain. They have since 
diverged and produced many new mutations and new traits. A similar experiment 
examining mutations in human cell lines rather than just the overall effects of selection 
under different culture conditions, might be useful to examine the effect of mutation rate 
on mutation incidence and patterns.  
With the addition of more samples from other tumor types, it would become more 
feasible to try to differentiate between effects of selection on genes due to their benefit to 
cancer cell survival, and the raw patterns of mutation that are imposed by the regulatory 
or genetic conditions creating the higher mutation rates. Perhaps growing immortalized 
cells with these mutation rate increasing disorders in culture and examining the mutations 
that occur over time, similar to how the Lenski experiment in bacteria were performed, 
would enable researchers to observe mutations in the cell populations as they occur. The 
key difficulty in this is that if the mutations are not selective, they would either be neutral 
or deleterious, and in either case may not spread to many cells, so the ability to detect 
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these changes in potentially one or two of thousands of cells requires very low sequencing 
error, so that the detected base changes remain above minimal quality acceptance 
criteria. Some of these cell lines are already heavily mutated, so it might be better to start 
with the youngest stock cultures available, in terms of number of generations of cells since 
collection from the patient or derivation of the cell line. 
To some extent this experiment has already been done, albeit in an much less 
controlled and methodical way than with the Lenksi E.coli project, with the long-term use 
of immortalized human cell cultures such as HeLa cells. Samples from various time points 
in the culturing of HeLa cells exist in labs all over the world, as does sequencing data for 
many of these samples. This existing data could be mined to reconstruct a picture of what 
has been happening, genomically, within these cells as they have been used in 
experiments over the decades they have been in use. This data could also be used in 
conjunction with a follow-up project keeping these cell lines in a more methodical 
experimental setup. Some of the cultures could be given a starting DNA repair deficit by 
deleting or mutating one or more of several known repair-related genes in such a way as 
to significantly raise unrepaired mutation rates. Then the results between the different 
cultures could be compared over time. 
Concluding Thoughts 
I have shown that there were differences in mutation pattern between tumors with 
a lot of mutations and those will smaller numbers of mutations. I have examined some of 
these differences in greater detail, and identified the genes that were most affected by 
the conditions that led to this difference in amount of total mutation. Some of these genes 
were clearly more affected due to size, but there also appeared to be a subset of cancer 
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related genes that were affected by selection in one population or the other. This 
phenomenon needs further study to determine causative mechanisms of these 
differences. It is also necessary to attempt to explain what is driving the genomic instability 
of the microsatellite stable tumors with very high mutation counts.  
I have also highlighted the importance of determining whether a mutation that is 
structurally deleterious actually contributes to cancer. It is not sufficient for a gene to be 
known to be cancer related, or part of a known tumorigenic pathway, or to have mutations 
causing structural alterations, even destructive ones to be classified as a driver. For 
example, in oncogenes, which require an activating mutation to cause cancer, a 
deactivating mutation would simply be a passenger mutation. Many existing predictive 
analysis programs lack the ability to make this important distinction and assign misleading 
predictions based on gene ontology and/or structural predictions, but without 
consideration for which specific mutations are actually capable of being tumor drivers and 
which are not.  
To this end there must be a greater effort to determine which genes appearing to 
be frequently mutated in cancer are actually capable of being cancer drivers, whether 
they are oncogenes or tumor suppressors, and where the activating mutations of 
oncogenes are located.  
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